The Board of Directors of Deep Health AI India Limited , formerly known as Deep Diamond India Limited, convened a meeting on May 04, 2026, at its registered office located at 506-509, Fifth Floor, Apeksha, Plot No. 256, Sector 11, Udaipur, Rajasthan. The meeting commenced at 02:30 P.M. and concluded at 04:00 P.M. During the meeting, the board considered and approved a proposal to raise funds through a rights issue of fully paid-up equity shares to eligible existing shareholders.

Rights Issue Approval

The board approved raising funds through the issue of fully paid-up equity shares on a rights basis to the existing equity shareholders of the company, for an amount aggregating up to Rs. 25.00 crores (Rupees Twenty-Five Crores). The issue is subject to receipt of statutory and regulatory approvals in accordance with the provisions of the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and other applicable laws. The record date for determining eligible shareholders is yet to be determined and will be notified subsequently.

The key details of the proposed rights issue, as disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are as follows:

Rights Issue Committee Constituted

To give effect to the rights issue, the board constituted a Rights Issue Committee and authorised its members to decide on the terms and conditions of the issue. The committee's mandate includes, but is not limited to, the following:

• Determining the final issue size and amount
• Fixing the rights entitlement ratio and issue price
• Setting the record date and schedule of the rights issue
• Approving the letter of offer
• Appointment of intermediaries and legal counsel, if required
• Allotment of shares and other related matters

Draft Letter of Offer and Regulatory Filing

The board also approved the Draft Letter of Offer for fund raising by way of the rights issue and authorised the company to apply for in-principal approval for the rights issue of up to Rs. 25.00 crores under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The outcome of the board meeting was communicated to BSE Limited under Regulation 30 of the SEBI Listing Regulations. The disclosure was signed by Narayan Singh Rathore, Managing Director of the company.

Deep Health AI India Limited (formerly known as Deep Diamond India Limited) has successfully completed the relocation of its registered office from Maharashtra to Rajasthan, marking a significant administrative milestone for the pharmaceutical and healthcare company.

Regulatory Compliance and Notification

The company formally notified BSE Limited on April 14, 2026, regarding the completion of its registered office relocation in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Managing Director Narayan Singh Rathore signed the official communication, confirming all regulatory requirements had been fulfilled.

Office Relocation Details

The registered office has been shifted from its previous location at "309, 3rd Floor, V Star Plaza Plot No. 16 Chandavarkar Road, Opp. Saraswat Bank, Opposite Raj Mahal Hotel, Borivali West, Maharashtra, India, 400092" to the new address at "506-509, 5th Floor, Apeksha, Plot No. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan-313001."

Regulatory Approvals and Documentation

The Ministry of Corporate Affairs issued the Certificate of Registration of Regional Director's Order for change of State on March 26, 2026. This certificate was signed by Atma Sah, serving as Assistant Registrar of Companies/Deputy Registrar of Companies/Registrar of Companies at ROC Jaipur. The interstate relocation required approval from the Regional Director (Western Region), which was granted through an order dated February 09, 2026.

Corporate Identity Updates

Following the successful relocation, the company's Corporate Identity Number (CIN) has been updated to L24100RJ1994PLC112895, reflecting the change in state jurisdiction from Maharashtra (MH) to Rajasthan (RJ). The company continues to operate under its current name, Deep Health AI India Limited, having previously been known as Deep Diamond India Limited.

Shareholder Approval Process

The registered office relocation was initially approved through a special resolution passed by shareholders in the Annual General Meeting held on September 27, 2024. The Memorandum of Association was subsequently amended to reflect the change in registered office clause, with the Regional Director's confirmation received on February 09, 2026.

Business Operations and Focus

According to the company's Memorandum of Association, Deep Health AI India Limited operates in the pharmaceutical and healthcare sector, focusing on manufacturing, marketing, and distribution of drugs, pharmaceuticals, and medical products. The company's business activities include research and development in biotechnology, biochemical processes, and various pharmaceutical formulations including tablets, capsules, and medical equipment.